These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17531483)

  • 1. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.
    Islam I; Brown G; Bryant J; Hrvatin P; Kochanny MJ; Phillips GB; Yuan S; Adler M; Whitlow M; Lentz D; Polokoff MA; Wu J; Shen J; Walters J; Ho E; Subramanyam B; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3819-25. PubMed ID: 17544272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based optimization of potent PDK1 inhibitors.
    Angiolini M; Banfi P; Casale E; Casuscelli F; Fiorelli C; Saccardo MB; Silvagni M; Zuccotto F
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4095-9. PubMed ID: 20621725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
    Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 7-azaindoles as PDK1 inhibitors.
    Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, kinase inhibitory potencies and in vitro antiproliferative activity of isoindigo and 7'-azaisoindigo derivatives substituted by Sonogashira cross-coupling.
    Bouchikhi F; Anizon F; Moreau P
    Eur J Med Chem; 2009 Jun; 44(6):2705-10. PubMed ID: 19232788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).
    Nittoli T; Dushin RG; Ingalls C; Cheung K; Floyd MB; Fraser H; Olland A; Hu Y; Grosu G; Han X; Arndt K; Guo B; Wissner A
    Eur J Med Chem; 2010 Apr; 45(4):1379-86. PubMed ID: 20074837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening.
    Lee AC; Ramanujulu PM; Poulsen A; Williams M; Blanchard S; Ma DM; Bonday Z; Goh KL; Goh KC; Goh MK; Wood J; Dymock BW
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4023-7. PubMed ID: 22591730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse in silico screening for identification of kinase inhibitor targets.
    Zahler S; Tietze S; Totzke F; Kubbutat M; Meijer L; Vollmar AM; Apostolakis J
    Chem Biol; 2007 Nov; 14(11):1207-14. PubMed ID: 18022559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-aided optimization of kinase inhibitors derived from alsterpaullone.
    Kunick C; Zeng Z; Gussio R; Zaharevitz D; Leost M; Totzke F; Schächtele C; Kubbutat MH; Meijer L; Lemcke T
    Chembiochem; 2005 Mar; 6(3):541-9. PubMed ID: 15696597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
    Blanchard S; William AD; Lee AC; Poulsen A; Teo EL; Deng W; Tu N; Tan E; Goh KL; Ong WC; Ng CP; Goh KC; Bonday Z; Sun ET
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2443-7. PubMed ID: 20338758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.